Treatment of moderately to severely active ulcerative colitis with RO7790121 demonstrates early clinical response and symptom improvement: results from the Phase 2b Tuscany-2 trial

Jessica Allegretti; Andres Yarur; Brian Feagan; Silvio Danese; Stefan Schreiber; Laurent Peyrin-Biroulet; Jaroslaw Kierkus; Rupert Leong; Daniela Bojic; Karen Lasch; Courtney Schiffman; Vipul Jairath

doi:10.1053/j.gastro.2025.01.077

Treatment of moderately to severely active ulcerative colitis with RO7790121 demonstrates early clinical response and symptom improvement: results from the Phase 2b Tuscany-2 trial

Jessica Allegretti, Andres Yarur, Brian Feagan, Silvio Danese, Stefan Schreiber, Laurent Peyrin-Biroulet, Jaroslaw Kierkus, Rupert Leong, Daniela Bojic, Karen Lasch, Courtney Schiffman, Vipul Jairath

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	S17-S18
Number of pages	2
Journal	Gastroenterology
Volume	168
Issue number	3 Supplement
DOIs	https://doi.org/10.1053/j.gastro.2025.01.077
Publication status	Published - Feb 2025
Event	Crohns & Colitis Congress - San Francisco, Canada Duration: 6 Feb 2025 → 8 Feb 2025

Access to Document

10.1053/j.gastro.2025.01.077

Cite this

Allegretti, J., Yarur, A., Feagan, B., Danese, S., Schreiber, S., Peyrin-Biroulet, L., Kierkus, J., Leong, R., Bojic, D., Lasch, K., Schiffman, C., & Jairath, V. (2025). Treatment of moderately to severely active ulcerative colitis with RO7790121 demonstrates early clinical response and symptom improvement: results from the Phase 2b Tuscany-2 trial. Gastroenterology, 168(3 Supplement), S17-S18. https://doi.org/10.1053/j.gastro.2025.01.077

@article{d43419afbaaa45ca896531a3d97e48f1,

title = "Treatment of moderately to severely active ulcerative colitis with RO7790121 demonstrates early clinical response and symptom improvement: results from the Phase 2b Tuscany-2 trial",

author = "Jessica Allegretti and Andres Yarur and Brian Feagan and Silvio Danese and Stefan Schreiber and Laurent Peyrin-Biroulet and Jaroslaw Kierkus and Rupert Leong and Daniela Bojic and Karen Lasch and Courtney Schiffman and Vipul Jairath",

year = "2025",

month = feb,

doi = "10.1053/j.gastro.2025.01.077",

language = "English",

volume = "168",

pages = "S17--S18",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W. B. Saunders",

number = "3 Supplement",

note = "Crohns & Colitis Congress ; Conference date: 06-02-2025 Through 08-02-2025",

}

Allegretti, J, Yarur, A, Feagan, B, Danese, S, Schreiber, S, Peyrin-Biroulet, L, Kierkus, J, Leong, R, Bojic, D, Lasch, K, Schiffman, C & Jairath, V 2025, 'Treatment of moderately to severely active ulcerative colitis with RO7790121 demonstrates early clinical response and symptom improvement: results from the Phase 2b Tuscany-2 trial', Gastroenterology, vol. 168, no. 3 Supplement, pp. S17-S18. https://doi.org/10.1053/j.gastro.2025.01.077

Treatment of moderately to severely active ulcerative colitis with RO7790121 demonstrates early clinical response and symptom improvement: results from the Phase 2b Tuscany-2 trial. / Allegretti, Jessica; Yarur, Andres; Feagan, Brian et al.
In: Gastroenterology, Vol. 168, No. 3 Supplement, 02.2025, p. S17-S18.

Research output: Contribution to journal › Meeting abstract › peer-review

TY - JOUR

T1 - Treatment of moderately to severely active ulcerative colitis with RO7790121 demonstrates early clinical response and symptom improvement

T2 - Crohns & Colitis Congress

AU - Allegretti, Jessica

AU - Yarur, Andres

AU - Feagan, Brian

AU - Danese, Silvio

AU - Schreiber, Stefan

AU - Peyrin-Biroulet, Laurent

AU - Kierkus, Jaroslaw

AU - Leong, Rupert

AU - Bojic, Daniela

AU - Lasch, Karen

AU - Schiffman, Courtney

AU - Jairath, Vipul

PY - 2025/2

Y1 - 2025/2

U2 - 10.1053/j.gastro.2025.01.077

DO - 10.1053/j.gastro.2025.01.077

M3 - Meeting abstract

SN - 0016-5085

VL - 168

SP - S17-S18

JO - Gastroenterology

JF - Gastroenterology

IS - 3 Supplement

Y2 - 6 February 2025 through 8 February 2025

ER -